Silvia Bernat

Villarreal De Alava, PV, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Early Use of Fostamatinib in Immune Thrombocytopenia.

Early Use of Fostamatinib in Immune Thrombocytopenia.

Journal: Advances in therapy

Published: June 02, 2026

Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).

Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).

Journal: American journal of hematology

Published: August 13, 2024

Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques.

Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques.

Journal: Blood vessels, thrombosis & hemostasis

Published: May 20, 2024

Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.

Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.

Journal: Platelets

Published: May 14, 2024

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.

Journal: Blood

Published: February 08, 2024

Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.

Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.

Journal: Blood reviews

Published: March 23, 2023

Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group.

Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group.

Journal: Infectious diseases and therapy

Published: November 02, 2022

Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.

Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.

Journal: European journal of haematology

Published: October 08, 2019

Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.

Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.

Journal: International journal of hematology

Published: January 18, 2017

Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.

Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.

Journal: British journal of haematology

Published: January 02, 2017

Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.

Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.

Journal: European journal of haematology

Published: December 17, 2015

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.

Journal: American journal of hematology

Published: October 01, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026